Cognitive Effects of ARPIs in Prostate Cancer: Darolutamide Outperforms Enzalutamide
The ARACOG trial has provided critical comparative data on Androgen Receptor Pathway Inhibitors (ARPIs) in prostate cancer treatment. Findings indicate that patients treated with enzalutamide experienced a higher incidence of ... Read More